Evaluation of a modified thromboelastography assay for the screening of von Willebrand disease

Thrombosis and Haemostasis

Volumn 105, Issue 6, 2011, Pages 1091-1099

  Topf, Hans Georg ^a   Weiss, Dominik ^a   Lischetzki, Grischa ^a   Strasser, Erwin ^a   Rascher, Wolfgang ^a   Rauh, Manfred ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Point of care; Rotem; Thromboelastography; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; COLLAGEN; DESMOPRESSIN; FIBRIN; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CONCENTRATE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DRUG ACTIVITY; DRUG MONITORING; FAMILY HISTORY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BINDING; SCHOOL CHILD; SCREENING TEST; SENSITIVITY AND SPECIFICITY; THROMBOCYTE AGGLUTINATION; THROMBOELASTOGRAPHY; TREATMENT RESPONSE; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEASIBILITY STUDIES; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; REFERENCE VALUES; ROC CURVE; THROMBELASTOGRAPHY; VON WILLEBRAND DISEASES;

EID: 79958141410     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-12-0782     Document Type: Article

References (38)

1. Budde U, Schneppenheim R. Von Willebrand factor and von Willebrand disease. Rev Clin Exp Hematol 2001; 5: 335-368.
2. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-2114.
3. Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol 2007; 82: 368-375.
4. van Genderen PJ, Leenknegt H, Michiels JJ, et al. Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 1996; 22 (Suppl 1): 79-82.
5. Nichols WL, Rick ME, Ortel TL, et al. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol 2009; 84: 366-370.
6. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-773.
7. Budde U, Drewke E, Mainusch K, et al. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost 2002; 28: 173-190.
8. Woods AI, Blanco AN, Chuit R, et al. Major haemorrhage related to surgery in patients with type 1 and possible type 1 von Willebrand disease. Thromb Haemost 2008; 100: 797-802.
9. Israels SJ. Diagnostic evaluation of platelet function disorders in neonates and children: an update. Semin Thromb Hemost 2009; 35: 181-188.
10. Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010; 104: 1009-1021.
11. Udvardy ML, Szekeres-Csiki K, Harsfalvi J. Novel evaluation method for densitometric curves of von Willebrand factor multimers and a new parameter (M(MW) to describe the degree of multimersation. Thromb Haemost 2009; 102: 412-417.
12. Corrales I, Ramirez L, Altisent C, et al. Rapid molecular diagnosis of von Willebrand disease by direct sequencing. Detection of 12 novel putative mutations in VWF gene. Thromb Haemost 2009; 101: 570-576.
13. Frontroth JP, Hepner M, Sciuccati G, et al. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children. Thromb Haemost 2010; 104: 1158-1165.
14. Sutor AH. The bleeding time in pediatrics. Semin Thromb Hemost 1998; 24: 531-543.
15. Dean JA, Blanchette VS, Carcao MD, et al. von Willebrand disease in a pediatricbased population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost 2000; 84: 401-409.
16. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34: 709-733.
17. Cattaneo M, Federici AB, Lecchi A, et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82: 35-39.
18. Akin M, Karapinar DY, Balkan C, et al. An Evaluation of the DDAVP Infusion Test With PFA-100 and vWF Activity Assays to Distinguish vWD Types in Children. Clin Appl Thromb Hemost 2010; epub ahead of print.
19. Roschitz B, Thaller S, Koestenberger M, et al. PFA-100 closure times in preoperative screening in 500 pediatric patients. Thromb Haemost 2007; 98: 243-247.
20. Favaloro EJ. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 2001; 7: 170-179.
21. Favaloro EJ. Rethinking the diagnosis of von Willebrand disease. Thromb Res 2011; 127 (Suppl 2): S17-S21.
22. Nair SC, Dargaud Y, Chitlur M, et al. Tests of global haemostasis and their applications in bleeding disorders. Haemophilia 2010; 16 (Suppl 5): 85-92.
23. Perry DJ, Fitzmaurice DA, Kitchen S, et al. Point-of-care testing in haemostasis. Br J Haematol 2010; 150: 501-514.
24. Reikvam H, Steien E, Hauge B, et al. Thrombelastography. Transfus Apher Sci 2009; 40: 119-123.
25. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27: 81-90.
26. Huissoud C, Carrabin N, Benchaib M, et al. Coagulation assessment by rotation thrombelastometry in normal pregnancy. Thromb Haemost 2009; 101: 755-761.
27. Scharbert G, Auer A, Kozek-Langenecker S. Evaluation of the Platelet Mapping Assay on rotational thromboelastometry ROTEM. Platelets 2009; 20: 125-130.
28. Sanchez-Luceros A, Meschengieser SS, Woods AI, et al. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history. Thromb Haemost 2010; 104: 984-989.
29. Weiss DR, Thiel C, Strasser EF, et al. An optimized electrophoresis method for high-resolution imaging of von-Willebrand multimers. Thromb Haemost 2008; 100: 949-951.
30. Cariappa R, Wilhite TR, Parvin CA, et al. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol 2003; 25: 474-479.
31. Williams CD, Cherala G, Serebruany V. Application of platelet function testing to the bedside. Thromb Haemost 2010; 103: 29-33.
32. Theusinger OM, Baulig W, Asmis LM, et al. In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM). Thromb Haemost 2010; 104: 385-391.
33. Oswald E, Stalzer B, Heitz E, et al. Thromboelastometry (ROTEM) in children: age-related reference ranges and correlations with standard coagulation tests. Br J Anaesth 2010; 105: 827-835.
34. Strauss T, Levy-Shraga Y, Ravid B, et al. Clot formation of neonates tested by thromboelastography correlates with gestational age. Thromb Haemost 2010; 103: 344-350.
35. Huissoud C, Carrabin N, Audibert F, et al. Bedside assessment of fibrinogen level in postpartum haemorrhage by thrombelastometry. Br J Obstet Gyn 2009; 116: 1097-1102.
36. van Vliet HH, Kappers-Klunne MC, Leebeek FW, et al. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Thromb Haemost 2008; 100: 462-468.
37. Fressinaud E, Veyradier A, Sigaud M, et al. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates. Br J Haematol 1999; 106: 777-783.
38. Lenting PJ, Pegon JN, Groot E, et al. Regulation of von Willebrand factor-platelet interactions. Thromb Haemost 2010; 104: 449-455.